SEHK:1316
SEHK:1316Auto Components

Assessing Nexteer Automotive Group (SEHK:1316) Valuation After Hervé Boyer’s Resignation Draws Fresh Attention

Why Hervé Boyer’s Exit Is Drawing Fresh Attention to Nexteer Automotive Group (SEHK:1316) Hervé Boyer’s upcoming resignation as executive director and global COO has put Nexteer Automotive Group (SEHK:1316) firmly on investors’ radar, as leadership changes often raise questions about continuity and future priorities. See our latest analysis for Nexteer Automotive Group. Nexteer’s HK$7.31 share price sits against a backdrop of a 19.44% 30 day share price return and a 132.92% 1 year total...
SEHK:489
SEHK:489Auto

Assessing Dongfeng Motor Group (SEHK:489) Valuation After Strong December 2025 NEV Production And Sales Update

Production and sales update that put Dongfeng Motor Group (SEHK:489) in focus Dongfeng Motor Group (SEHK:489) has come into focus after reporting unaudited December 2025 figures, with total production of 231,656 units and sales of 199,160 units, including expanding new energy vehicle volumes. See our latest analysis for Dongfeng Motor Group. At a share price of HK$9.08, Dongfeng Motor Group has had a firm start to the year, with a 7 day share price return of 4.73% and a 1 year total...
SEHK:2276
SEHK:2276Medical Equipment

Shanghai Conant Optical (SEHK:2276) Valuation After Guidance For At Least 30% Profit Growth In 2025

Why Shanghai Conant Optical issued fresh 2025 profit guidance Shanghai Conant Optical (SEHK:2276) has issued new guidance for 2025, telling investors it expects net profit attributable to shareholders to be at least 30% higher than in 2024. The company links this outlook to stronger sales of high refractive index 1.74 lenses and other multifunctional products, greater economies of scale, higher automation levels, and efforts to optimize its financing structure, capital return, and financing...
SEHK:1519
SEHK:1519Logistics

Assessing J&T Global Express (SEHK:1519) Valuation After Mixed Short-Term Moves And Stronger One-Year Momentum

What recent performance says about J&T Global Express Even without a single headline catalyst, J&T Global Express (SEHK:1519) has given investors plenty to think about, with the share price showing mixed shorter term moves alongside stronger figures over the past 3 months and year. See our latest analysis for J&T Global Express. At the current share price of HK$11.4, J&T Global Express has seen short term share price pressure with a 1-day and 7-day share price decline, while its 30-day and...
SEHK:6990
SEHK:6990Biotechs

Does Breakthrough Status For Sacituzumab Tirumotecan-Keytruda Combo Reshape Kelun-Biotech’s Oncology Strategy (SEHK:6990)?

Sichuan Kelun-Biotech Biopharmaceutical recently announced that its TROP2-directed ADC sacituzumab tirumotecan, combined with MSD’s KEYTRUDA, received Breakthrough Therapy Designation in China for first-line treatment of certain advanced non-small cell lung cancer patients, while its CEO highlighted pipeline progress and globalisation plans at the J.P. Morgan Healthcare Conference. The clustering of multiple Breakthrough Therapy Designations around sacituzumab tirumotecan, alongside...
SEHK:1783
SEHK:1783Construction

Will Envision Greenwise’s New Board Lineup Strengthen Its Governance Story For Investors (SEHK:1783)?

Envision Greenwise Holdings has appointed veteran finance executive Fei Yiping as a non-executive director from 16 January 2026, while also confirming its full board and committee structure to align with Hong Kong listing requirements. Fei’s long tenure in senior finance roles at major Chinese and international businesses adds heavyweight accounting and governance expertise to Envision Greenwise’s boardroom. Next, we’ll examine how Fei Yiping’s appointment and broader board reshaping may...